The multi-biomarker disease activity (MBDA) score, an algorithm based on 12 serological markers, helped subdivide patients with anti-citrullinated protein antibody (ACPA)-negative rheumatoid arthritis (RA) into clinically relevant subsets in a multivariable analysis. Patients with a high or medium MBDA score at the time of diagnosis had a higher likelihood of sustained DMARD-free remission than patients with a low score (P = 0.115). This association was independent of clinical baseline characteristics and driven primarily by levels of C-reactive protein, serum amyloid A and matrix metalloproteinase 3.
References
Original article
Boeters, D. M. et al. ACPA-negative RA consists of subgroups: patients with high likelihood of achieving sustained DMARD-free remission can be identified by serological markers at disease presentation. Arthritis Res. Ther. 21, 121 (2019)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
McHugh, J. ACPA-negative RA divided into clinical subsets. Nat Rev Rheumatol 15, 384 (2019). https://doi.org/10.1038/s41584-019-0245-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-019-0245-3
